CRISPR THERAPEUTICS Aktie

 

New York (www.aktiencheck.de) - CRISPR Therapeutics-Aktienanalyse von J.P. Morgan Securities: Der Analyst Brian Cheng von JPMorgan hat die Coverage der Aktie der CRISPR Therapeutics AG (ISIN: CH0334081137, WKN: A2AT0Z, Ticker-Symbol: 1CG, NASDAQ-Symbol: CRSP) mit einem "overweight"-Rating und einem Kursziel von 70 USD aufgenommen. [mehr]...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $59.07, marking a -3.46% move from the previous day....

read more...

Based on the average brokerage recommendation (ABR), CRISPR Therapeutics (CRSP) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?...

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $51.81, indicating a -3.5% shift from the previous trading day....

ZUG, Switzerland and BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that a late-breaking oral presentation highlighting the Company's Phase 1 clinical data of its investigational CRISPR/Cas9 in vivo gene editing therapy, CTX310™, targeting angiopoietin-related protein 3 (ANGPTL3) for cardiovascular and cardiometabolic disease, will be presented at the American Heart Association (AHA) Scientific Sessions 2025, taking place November 7 – 10, 2025, in New Orleans, Louisiana. Additionally, the Company will present a poster presentation on CTX340™, its in vivo preclinical program targeting angiotensinogen (AGT) for the treatment of refractory hypertension....

This little company's scientific breakthrough opened up a whole new sliver of the drug market (although it's still leading the developmental race)....

CRISPR Therapeutics pushes beyond Casgevy with in vivo programs like CTX310, CTX320 and plans for two more studies by 2025-end....

Die Star-Investorin hat seit Wochen ein gesteigertes Interesse am Biotech-Sektor, wie die Handelsstatistiken des ARK Innovation Fund zeigen. Besonders CRISPR Therapeutics hat es Cathie Wood angetan. Die Aktie des Gen-Schere-Spezialisten steht fast täglich auf ihrer Einkaufsliste....

Kulkarni, Samarth - Vorstand - Tag der Transaktion: 2025-08-18...

CRSP's Casgevy records a 114% sales jump sequentially in Q2, fueling optimism for sustained revenues and long-term growth....

Treco, Douglas A. - Aufsichtsrat - Tag der Transaktion: 2025-08-06...

-CASGEVY® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 patients have had cells collected across all regions; positioning the program for strong future growth-...

As time marches on, the factors that could make or break this stock are becoming crystal clear....

CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress....

CRISPR Therapeutics (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

Ark Invest traded in VCYT, IRDM, CRSP, KTOS, ABSI, VEEV, ADPT, and GH. Mainly focused on healthcare innovation. read more...

CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $64.76, signifying a -1.97% move from its prior day's close....

Bereits zum Monatsanfang hat die Aktie des Gen-Schere-Spezialisten CRISPR Therapeutics wieder an Fahrt aufgenommen. Am Freitag verzeichnet der AKTIONÄR-Depotwert erneut einen zweistelligen Kursanstieg. Während daher die Bullen jubeln, sind die Bären besonders enttäuscht....